Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jesus Martin-Garcia | Chairman & CEO | 537k | -- | 1962 |
| Mr. Miguel Payró | Group Chief Financial Officer | -- | -- | 1965 |
| Dr. Hervé Perron HDR, Ph.D. | Chief Scientific Officer | -- | -- | 1959 |
| Dr. Alois B. Lang Ph.D. | Chief Development Officer | -- | -- | 1952 |
| Dr. Anke Post M.D., Ph.D. | Chief Medical Officer | -- | -- | 1966 |
GeNeuro SA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 17
Description
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301. In addition, It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
Corporate Governance
Upcoming Events
December 16, 2024 at 5:00 PM UTC - December 17, 2024 at 5:00 PM UTC
GeNeuro SA Earnings Date
Recent Events
Recent Events Information Not Available